NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Wed, 10/25/2017 - 22:43

There are no breaks during the review process or award decisions (eg, review & payline is the same for all applicants). Specific R03 PARs are limited to K awardees in certain ICs, so those R03s get special consideration, but otherwise, no. The goal is to get new investigators to put their time and energy into R01 applications, which do have review and payline breaks plus bigger budgets and the potential for renewal (and are hence the platform on which to establish an independent research career, not an R21 or R03).

Categories: NIH-Funding

By: Question

WriteEdit-Grant Questions Blog - Wed, 10/25/2017 - 19:12

Is early investigator status noted or relevant for R21 and R03 grants? That is, do early investigators get a boost for R21/R03 grants, or just R01s? Thanks for your help.

Categories: NIH-Funding

By: SkinDoc

WriteEdit-Grant Questions Blog - Wed, 10/25/2017 - 16:02

We’re investigating blood vessel-nerve interactions in hypertensives so it went to NHLBI and CICS…my other R01s have gone to NIAMS but haven’t had any luck there even getting scored.

Categories: NIH-Funding

NIH Plans for Clinical Trial Specific Parent R01 and Parent R21 Funding Opportunity Announcements

NIH Funding Announcements - Wed, 10/25/2017 - 13:48
Notice NOT-OD-18-010 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Wed, 10/25/2017 - 13:24

As SaG said, this will be FY18, and you should be in good shape, even though there is no break for NI applicants – only ESI. The initial paylines will be very conservative, but by the time your application comes up for funding, the federal budget should be in place … and even if not, higher paylines later in the FY are retrospective to the prior cycles.

Categories: NIH-Funding

By: SaG

WriteEdit-Grant Questions Blog - Wed, 10/25/2017 - 12:47

FY2018. According to the current House and Senate NIH Bills I would expect a similar payline in 2018 as 2017. Assuming no changes in NHLBI funding policies. Of course this begs the question of why skindoc isn’t applying to NIAMS……

Categories: NIH-Funding

Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3) - Clinical Trial Required

NIH Funding Announcements - Wed, 10/25/2017 - 12:41
Funding Opportunity PAR-18-407 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center for investigator-initiated multi-site clinical trials (Phase II and beyond). Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website: http://www.nhlbi.nih.gov. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-16-301). The objective of the Clinical Coordinating Center application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should include plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a Clinical Coordinating Center (CCC) application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.
Categories: NIH-Funding

Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)

NIH Funding Announcements - Wed, 10/25/2017 - 12:41
Funding Opportunity PAR-18-410 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials (Phase II and beyond). Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the definition of an NIH clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Clinical Coordinating Center (PAR-FY-NNN). The DCC application must be specific for the clinical trial being proposed in the collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.
Categories: NIH-Funding

Outstanding New Environmental Scientist (ONES) Award (R01 Clinical Trial Optional)

NIH Funding Announcements - Wed, 10/25/2017 - 11:39
Funding Opportunity RFA-ES-18-001 from the NIH Guide for Grants and Contracts. The Outstanding New Environmental Scientist (ONES) Award is intended to identify the most talented Early Stage Investigators (ESIs) who intend to make a long-term commitment to research in the Environmental Health Sciences and assist them in launching an innovative research program focused on the understanding of environmental exposure effects on peoples health.
Categories: NIH-Funding

Immunity in the Elderly (R01) Clinical Trial Optional

NIH Funding Announcements - Wed, 10/25/2017 - 11:13
Funding Opportunity RFA-AI-17-037 from the NIH Guide for Grants and Contracts. The goal of this reissued Funding Opportunity Announcement (FOA) is to expand understanding of age-related changes that occur in immune function during the aging process that influence responses to pathogens and/or vaccines, as well as oral and craniofacial health. Human studies are required, and inclusion of relevant animal studies is permitted for mechanistic understanding. This FOA solicits applications that will determine the mechanisms required for induction and maintenance of protective immunity in the elderly in response to infections and/or vaccinations, including the effects of chronic inflammation on those responses, and applications that will assess changes in immune processes in dental, oral and craniofacial tissues in the elderly.
Categories: NIH-Funding

Role of Peripheral Proteostasis on Brain Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 10/25/2017 - 10:58
Funding Opportunity RFA-AG-18-020 from the NIH Guide for Grants and Contracts. The National Institute on Aging (NIA) solicits research projects that would advance our understanding of how protein homeostasis (proteostasis) in peripheral tissues affects brain aging, leading to the development of Alzheimers Disease (AD). Much research on AD has focused on the accumulation of aberrant protein aggregates in the brain, and in particular amyloid and Tau. Formation of aggregates due to mutations encoded in the APP gene or due to hyperphosphorylation, respectively, have been linked to familial AD. The etiology of the more common, sporadic form of AD, is less certain, although aging is considered a major risk for development of the disease. It is known that proteostasis is less efficiently maintained in all tissues with aging, and this may indicate a link between proteostasis in the periphery and the appearance of aging-related diseases and conditions, including the decline in cognitive function, as well as dementia and AD. Therefore, testing for a role of aging-related loss of peripheral proteostasis in the development of AD is the focus of this FOA.
Categories: NIH-Funding

Technology to Detect, Monitor and Assess Daily Functions in Individuals with Cognitive Decline, Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD) (R43/R44 Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 10/25/2017 - 10:40
Funding Opportunity PAR-18-329 from the NIH Guide for Grants and Contracts. This Small Business Innovation Research (SBIR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R and D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD).
Categories: NIH-Funding

Technology to Detect, Monitor and Assess Daily Functions in Individuals with Cognitive Decline, Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD) (R41/R42 Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 10/25/2017 - 10:40
Funding Opportunity PAR-18-326 from the NIH Guide for Grants and Contracts. This Small Business Technology Transfer (STTR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R and D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD).
Categories: NIH-Funding

By: SkinDoc

WriteEdit-Grant Questions Blog - Wed, 10/25/2017 - 10:12

I submitted an R01 in June 2017. It was sent to NHLBI and CICS study section. CICS met last week and my application received an impact score of 31 and was in the 9th percentile. NHLBI posted FY 2017 paylines are 15% so I think I’m in a good position…but, since council does not meet until January 2018 and the grant would not begin until April 2018 at the earliest, will my grant fall under FY 2017 or FY 2018? NHLBI has not posted their 2018 paylines (probably due to lack of a federal budget).
Should I be optimistic that my R01 will be funded? I’m a new investigator but not ESI (not sure that NI status does much for me).

Thanks for the input. This is a great site with great information.

Categories: NIH-Funding

Understanding the Early Development of the Immune System (R01 - Clinical Trial Not Allowed)

NIH Funding Announcements - Wed, 10/25/2017 - 10:04
Funding Opportunity PAR-18-333 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support studies on the very early development of the immune system and the humoral and cellular communication that exists between the mother and fetus that may shape or impact immune system development and maturation.
Categories: NIH-Funding

Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)

NIH Funding Announcements - Wed, 10/25/2017 - 03:00
Funding Opportunity PAR-18-406 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement phase II and beyond investigator-initiated single-site clinical trials. Applications submitted to this FOA must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website: http://www.nhlbi.nih.gov. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. It is anticipated that applications will present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes the conduct of the trial, as well as plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. Due to the complex nature of conducting a clinical trial, applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application. Staff will be able to assist applicants in meeting the objectives of this FOA.
Categories: NIH-Funding